Conclusions
Single agent carboplatin or CAP are as effective as carboplatin plus paclitaxel in the treatment of ovarian cancer.
The better side-effect profile of carboplatin alone makes it a reasonable first-line chemotherapeutic agent for ovarian cancer.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page